Inhibitor Therapeutics, Inc.
INTI
Price:
$0.05
Market Cap:
$8.63M
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Industry
Biotechnology
IPO Date
2013-09-13
Stock Exchange
OTC
Ticker
INTI
PE Ratio
[-2.50]
ROE
[-337.95%]
Current Ratio
[35.00]
Dividend Yield
[0%]
Enterprise Value
[5.72M]
Dividend History
The ROE as of December 2025 (TTM) for Inhibitor Therapeutics, Inc. (INTI) is -337.95%
According to Inhibitor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -337.95%. This represents a change of -93.51% compared to the average of -5208.94% of the last 4 quarters.
Inhibitor Therapeutics, Inc. (INTI) Historical ROE (quarterly & annually)
How has INTI ROE performed in the past?
The mean historical ROE of Inhibitor Therapeutics, Inc. over the last ten years is -1809.06%. The current -337.95% ROE has changed -81.32% with respect to the historical average. Over the past ten years (40 quarters), INTI's ROE was at its highest in in the March 2016 quarter at 369.90%. The ROE was at its lowest in in the September 2025 quarter at -20625.08%.
Average
-1809.06%
Median
-78.42%
Minimum
-14064.48%
Maximum
145.92%
Inhibitor Therapeutics, Inc. (INTI) ROE by Quarter and Year
Discovering the peaks and valleys of Inhibitor Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.98%
Maximum Annual ROE = 145.92%
Minimum Annual Increase = -139.25%
Minimum Annual ROE = -14064.48%
| Year | ROE | Change |
|---|---|---|
| 2024 | -168.21% | 193.72% |
| 2023 | -57.27% | -139.25% |
| 2022 | 145.92% | 1.67% |
| 2021 | 8.26% | -73.75% |
| 2020 | 31.46% | -70.72% |
| 2019 | 107.42% | -100.76% |
| 2018 | -14064.48% | 359.25% |
| 2017 | -3062.50% | 2.98% |
| 2016 | -99.57% | -89.31% |
| 2015 | -931.65% | -85.45% |
Inhibitor Therapeutics, Inc. (INTI) Average ROE
How has INTI ROE performed in the past?
The current ROE of Inhibitor Therapeutics, Inc. (INTI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-26.52%
5-year avg
-7.97%
10-year avg
-1809.06%
Inhibitor Therapeutics, Inc. (INTI) ROE vs. Peers
How is INTI’s ROE compared to its peers?
Inhibitor Therapeutics, Inc.’s ROE is less than LianBio (0.77%), greater than Oxford BioDynamics Plc (-244.86%), greater than Devonian Health Group Inc. (-33.54%), greater than Chimeric Therapeutics Limited (-167.90%), greater than Quantum Genomics S.A. (-156.81%), less than Curative Biotechnology, Inc. (65.29%), less than Nymox Pharmaceutical Corporation (24.07%), less than BetterLife Pharma Inc. (17.44%), greater than PharmaTher Holdings Ltd. (-106.37%), less than Nass Valley Gateway Ltd. (20.98%),
| Company | ROE | Market cap |
|---|---|---|
| 0.77% | $11.68M | |
| -244.86% | $8.95M | |
| -33.54% | $10.55M | |
| -167.90% | $7.10M | |
| -156.81% | $6.96M | |
| 65.29% | $8.16M | |
| 24.07% | $4.92M | |
| 17.44% | $8.85M | |
| -106.37% | $7.92M | |
| 20.98% | $8.48M |
Build a custom stock screener for Inhibitor Therapeutics, Inc. (INTI) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibitor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Inhibitor Therapeutics, Inc. (INTI) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Inhibitor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Inhibitor Therapeutics, Inc.'s ROE?
How is the ROE calculated for Inhibitor Therapeutics, Inc. (INTI)?
What is the highest ROE for Inhibitor Therapeutics, Inc. (INTI)?
What is the 3-year average ROE for Inhibitor Therapeutics, Inc. (INTI)?
What is the 5-year average ROE for Inhibitor Therapeutics, Inc. (INTI)?
How does the current ROE for Inhibitor Therapeutics, Inc. (INTI) compare to its historical average?